Highlights

  • Neurizon expanded Regimen I of the HEALEY ALS Platform Trial from 160 to 240 participants.
  • The larger cohort is intended to improve statistical strength and biomarker analysis.
  • Topline trial results are now expected in early Q3 CY2027.
  • The expanded study is expected to have no impact on costs through topline results.
  • As of 22 May 2026, 113 participants had been assigned and 74 had been dosed.

Neurizon Therapeutics Ltd (ASX:NUZ) remained in investor focus during the morning session on 27 May 2026 after the clinical-stage biotechnology company announced an expansion of its HEALEY ALS Platform Trial, a development the company believes could strengthen the long-term strategic and commercial positioning of its lead drug candidate, NUZ-001.

The update comes as Neurizon continues advancing treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS), also known as motor neurone disease. Although the company’s shares edged only modestly higher by 1.61% to AUD 0.063 during morning trade, the announcement marked an operational milestone for the biotech group, particularly given the increased scale of the trial and accelerated enrolment momentum.

Despite the day’s gain, Neurizon shares remain down approximately 58% over the past year, reflecting the broader Volatility often associated with early-stage biotechnology companies and clinical development programs.

HEALEY ALS Trial Cohort Expanded to 240 Participants

Neurizon announced that Regimen I of the HEALEY ALS Platform Trial will increase from 160 to 240 participants, with the company citing stronger-than-expected enrolment rates and the absence of a concurrent regimen during the recruitment period as key reasons behind the decision.

The revised study structure will now include 180 participants receiving NUZ-001 alongside 60 placebo control participants.

According to the company, the larger participant group is intended to preserve the statistical assumptions underpinning the original study design while also enabling broader subgroup and biomarker analysis.

Management stated that the expanded dataset is expected to provide a more internally consistent and statistically meaningful trial outcome at the topline results stage.

The company also believes the increased participant base may improve future regulatory, partnering and commercial discussions related to NUZ-001.

Accelerated Recruitment Supports Earlier Timeline Expectations

Importantly, Neurizon indicated that the current pace of recruitment is expected to accelerate the overall study timeline despite the increase in participant numbers.

Based on current enrolment trends, the company now expects dosing of the final participant to occur during the second quarter of calendar year 2027, with topline results anticipated in early Q3 CY2027.

Management noted that these revised expectations exceed previous timeframe projections.

As of 22 May 2026, a total of 113 participants had already been assigned to Regimen I, while 74 participants had received dosing treatment.

The company also confirmed that 64 clinical trial sites across the United States are currently active and that 193 participants have been screened under the broader master protocol to date.

Neurizon acknowledged that future recruitment rates may fluctuate over time, although current momentum continues tracking ahead of earlier assumptions.

Financial Impact Remains Limited Despite Larger Trial Size

One of the key aspects highlighted in the announcement was that the expanded trial size is not expected to materially alter the company’s near-term funding requirements.

Neurizon stated that the increased participant cohort will be partially offset through philanthropic financial contributions from the Sean M. Healey & AMG Center for ALS at Mass General Brigham.

As a result, the company expects costs through to topline results to remain unchanged, with only a modest increase anticipated in the total cost of completing the full trial program.

Management also noted that some of the additional expenditure may be offset through eligibility under Australia’s Federal Government Research and Development Tax Incentive Program.

The company stated that the revised structure reflects continued focus on cost and Capital efficiency while ensuring the study remains fully funded through completion.

For biotechnology investors, funding certainty during late-stage clinical programs is often considered an important Factor, particularly given the high costs associated with neurological disease trials.

Expanded Dataset May Improve Commercial Positioning

Neurizon believes the larger trial cohort could improve the overall strategic value of the NUZ-001 program.

The company indicated that the expanded and internally consistent dataset may strengthen future partnering opportunities and improve the quality of biomarker and translational insights generated during the study.

Management also stated that the trial structure removes reliance on placebo groups from other regimens within the broader platform trial, which may assist in maintaining statistical integrity at the topline results stage.

Interim Executive Chairman Sergio Duchini said the decision reflected confidence in NUZ-001 and highlighted the favourable recruitment momentum being delivered across the HEALEY ALS Platform Trial network.

He also noted that the expanded participant base is expected to strengthen the interpretability and broader value of the clinical program as the company progresses toward topline results.

According to management, ALS continues to represent a significant unmet medical need globally, and the company believes the expanded study may further improve Neurizon’s positioning as NUZ-001 advances through late-stage clinical development.

What Is the HEALEY ALS Platform Trial?

The HEALEY ALS Platform Trial is a multicentre, double-blind, placebo-controlled adaptive Phase 2/3 study conducted in the United States.

The trial is operated by the Sean M. Healey & AMG Center for ALS at Mass General Brigham in Partnership with the Network of Excellence for ALS, also known as NEALS.

Drug candidates entering the platform trial are selected following scientific review processes evaluating evidence of potential benefit for ALS patients.

The platform trial model is designed to accelerate development timelines for ALS treatments by allowing multiple therapeutic candidates to be assessed within a shared clinical infrastructure.

Neurizon’s lead candidate, NUZ-001, is currently being evaluated under Regimen I within this framework.

The company describes NUZ-001 as an investigational treatment targeting ALS and broader neurodegenerative disease applications, although the therapy has not been approved for commercial use in any Jurisdiction.

Industry and Research Community Continue Supporting ALS Development

The announcement also included comments from several leaders associated with the HEALEY ALS Platform Trial and broader research network.

Mass General Brigham Neuroscience Institute Executive Director Dr Merit Cudkowicz highlighted the collaborative nature of the partnership and noted the importance of maintaining patient-focused research efforts.

Meanwhile, Dr Sabrina Paganoni, Co-Principal Investigator of the HEALEY ALS Platform Trial, acknowledged the rapid enrolment progress achieved by investigators, site teams and participants involved in the study.

According to the update, the accelerated recruitment pace marks one of the fastest enrolment periods achieved within the network to date.

The broader ALS research community continues focusing on accelerating treatment development given the limited therapeutic Options currently available for patients affected by the disease.

Neurizon to Host Shareholder Webinar

Neurizon also announced plans to host an informational shareholder webinar on 28 May 2026 to discuss the expanded trial enrolment in more detail.

Management is expected to provide additional context regarding the updated trial design, timelines and broader implications for the NUZ-001 development program.

The company encouraged shareholders and investors to submit questions ahead of the session through the registration process or via company email channels.

Broader Company Focus Remains on Neurodegenerative Diseases

Neurizon Therapeutics is a clinical-stage biotechnology company focused on treatments for neurodegenerative conditions.

Its lead asset, NUZ-001, remains the company’s primary development program and is currently being advanced for the treatment of ALS.

Beyond ALS, the company has also highlighted potential future applications for NUZ-001 across broader neurodegenerative disease categories.

Neurizon’s strategy centres on accelerating access to potential therapies through international collaborations, platform trial participation and ongoing clinical development programs.

Today’s update appears to reinforce management’s focus on advancing the HEALEY ALS Platform Trial efficiently while balancing scientific, regulatory and financial considerations as the company moves closer toward topline data.